Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim Report January – June 2023

Copenhagen, Denmark, 24 August 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the interim report for the period January 1 – June 30, 2023. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.Curasight’s CEO Ulrich Krasilnikoff comments: “Q2 2023 represented one of the most strategically eventful quarters in Curasight’s history with the momentous achievement being the partnership agreement with Curium, a global leader in the industry. This partnership represents a

Axactor ASA: Amendment to bondholders’ summons

Oslo, Norway – 24 August 2023 – Axactor ASA FRN senior unsecured EUR 400,000,000 bonds 2021/2026 with NO0011093718 (the “Bond Issue”). Reference is made to the summons to a Bondholders' Meeting in the Bond Issue published on 17 August 2023 (the “Initial Summons”). Following discussions between the Issuer and certain Bondholders in advance of the Bondholders’ Meeting, the Issuer has agreed to make certain amendments to the amendment fee (as described in Clause 4 (Amendment fee) of the Initial Summons) by increasing the amendment fee from 0.25% of the Nominal Amount of the Outstanding Bonds

Eevia Health Plc receives a 130 KSEK / 11 KEUR sales order for a Chaga extract

Eevia Health Plc (”Eevia” or ”The Company”) has received an 11 KEUR sales order for Feno-Chaga®  Organic from a health-food customer in Finland.The direct customer is one of the largest well-being brand owners in Finland. It is one of the fastest-growing brand owners in the Superfood segment, with operations in several Nordic countries. Their selection has been supplemented with products that support comprehensive well-being, such as dietary supplements, drinks, and bars. The sales value to Eevia of this new order is c. KEUR 11 EUR. The product is a chaga extract standardized on beta-

Nanoform Q2 2023 – A record 11 new customer projects signed and targeting first license/commercial supply agreement in 2024

Company Announcement Nanoform Finland Plc August 24, 2023 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform Q2 2023 – A record 11 new customer projects signed and targeting first license/commercial supply agreement in 2024 A record (10+1) number of new projects signed in the second quarter. After receiving our “Multi-API” license in May, a further notification has been submitted to Fimea, including our new GMP lines, GMP QC laboratory and nanoforming of APIs to be used in products with a Marketing Authorization. The clinical manufacture for Project Blockbuster is

Circio Holding ASA – Second Tranche of Convertible Bonds

Reference is made to the Investment Agreement entered into between Atlas Special Opportunities, LLC (“Atlas”) and Circio Holding ASA (the “Company”) in connection with the issue by the Company of convertible bonds (the “Agreement”) and the convertible bond issue approved by an extraordinary general meeting of the Company on 9 March 2023. The Company has today by a notice of exercise under the Agreement requested Atlas to subscribe and pay for the second tranche of convertible bonds. The parties have agreed to reduce the tranche size to NOK 21.5m, payable in three installments of NOK 7.5m,

Second quarter 2023 financial results

Zalaris ASA (Zalaris, OSE:ZAL) reported record-high revenues in the second quarter of 2023 of NOK 280.5 million, up 33 percent from the same period in 2022, reflecting strong underlying fundamentals."The company grew more than 33 percent in the quarter, and 20 percent in constant currency, and delivered the sixth consecutive quarter with all time high revenues. We closed the first six month with all-time-high volume of new signings in Managed Services that in total generated around 90% of our sales target for the year, and we are well on track to deliver well above our target of generating

Kyoto Group: First half 2023 report and business update

Oslo, Norway, 24 August 2023 - Kyoto Group today reported its results for the first half of 2023. The company will also provide a live business update on the commercialization of its Heatcube thermal energy storage solution.“This year, Kyoto has taken several game-changing steps. We have concluded our first full-scale installation, we have been joined by two world-class strategic investors, and we have built a strong pipeline that we are committed to converting into commercial orders within the year. These events demonstrate the growing number of projects underway to decarbonize industrial

Paratus Energy Services Ltd – Improved Flexibility to Pursue Shareholder Returns and Release of Paratus Investor Presentation

Hamilton, Bermuda, August 24, 2023 - Paratus Energy Services Ltd. (“Paratus” or “Company”) today announced the effectiveness of the recent Paratus Notes amendment and release of the Company investor presentation. Effectiveness of July 2023 Amendment to the Notes, Improved Flexibility to Pursue Shareholder Capital Returns On July 28, 2023, Paratus announced the successful completion and effectiveness of the July 2023 amendment (“July 2023 Amendment”) to its Senior Secured Notes due 2026 (“Notes”). The July 2023 Amendment represents a significant milestone for the Company as it provides

Circio Holding ASA: First half 2023 results

Oslo, Norway, 24 August 2023 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA and immunotherapy medicines, today announces its first half 2023 results. Members of Circio’s executive management team will give an online presentation to investors, analysts and the press at 10:00 CET today (details below).FIRST HALF 2023 HIGHLIGHTS Corporate · The company was rebranded as Circio, an innovator in next generation circular RNA therapeutics · A convertible bond facility with Atlas Special Opportunities was established, securing up to NOK 300

Interim Report Q2, 2023: Acquisition of fast growing AI-based BrightBid

Speqta AB (publ) Interim Report for the period January 1 – June 30, 2023 is published and available on:https://speqta.com/en/investors/financial-reportSecond quarter results in brief · Revenues for the second quarter amounted to KSEK 1 958 (3 439). The decrease is explained by the transition from Shopello to Bidbrain which has a higher margin and long-term potential. During the third quarter the revenues from BrightBid will be included since the transaction was closed July 3, 2023. · EBITDA amounted to KSEK -8 481 (-12 356). · Earnings per share (including divested

Green Landscaping Group (publ) Interim report January-June 2023

24 August 2023, 07:00 CEST April-June 2023   · Net sales amounted to SEK 1,495 (1,134) million. · Growth was 32 percent, of which organic growth amounted to 4 percent. · EBITA increased by 51 percent to SEK 138 (92) million. · EBITA margin amounted to SEK 9.2 (8.1) percent. · Cash flow from operating activities amounted to SEK 80 (15) million. · Basic earnings per share were SEK 0.70 (0.81). · Diluted earnings per share were SEK 0.70 (0.81).   CEO comments   When closing the books on the second quarter of the year, I was able to conclude that the

SmartCraft ASA (SMCRT) – Q2 2023: Strong growth, record high EBITDA and continued positive market outlook

24 August 2023 - SmartCraft ASA, the leading Nordic provider of mission-critical SaaS solutions to small and mid-sized companies in the construction sector, today reported its results for the second quarter of 2023, ending the period with annual recurring revenue (ARR) of NOK 358 million, which represents a 12-month growth of 21 percent. Organic ARR growth was 15 percent. Reported revenue in the second quarter was NOK 101 million (+24 percent), of which 96 percent was recurring. Adjusted EBITDA margin increased by 7 percentage points to 44 percent, whereas reported EBITDA margin was 43

Finnish esports company UNEVN launches gaming setup that helps players move ahead in their professional career

Founded by Aleksi and Santeri Rinkinen together with former Dota 2 world champion Jesse “JerAx” Vainikka, the new BASE setup is designed to enable players to focus on what matters most.HELSINKI, Finland (August 24th, 2023) – Finnish esports company UNEVN has launched a new gaming setup meant for professional e-athletes and professionals-to-be. The new setup called BASE is designed to make organizing boot camps easier, improve performance, and help players move ahead in their career.   BASE is a portable gaming setup that comes with a high-end computer, screen, keyboard, mouse, and the

AcouSort AB - Interim Report for the period April– June 2023

Second quarter 2023 for the Group Net sales amounted to SEK 1,816,000 (715,000) Result before tax amounted to SEK -3,193,000 (-4,055,000) Result per share* was SEK -0.24 (-0.31) Equity ratio** amounted to 58% (88%) on June 30, 2023 Second quarter 2023 for the Parent company Net sales amounted to SEK 1,816,000 (715,000) Result before tax amounted to SEK -2,406,000 (-4,030,000) Result per share* was SEK -0.18 (-0.31) Equity ratio** amounted to 63% (88%) on June 30, 2023Significant events during the second quarter On April 3, AcouSort announces that the stem cell

Desert Control releases its H1 and Q2 2023 Report and Year-to-Date Company Update

Desert Control concludes strategic review, initiates transition to licensed operator model for the Middle East, delivers on target for the United States, and obtains key regulatory approvals. The Company closes the quarter with an outlook for significant cost reductions, improved capital efficiency, and strengthened liquidity.Sandnes, Norway, 24 August 2023 – Desert Control AS (DSRT) announces its second quarter and first half report for the fiscal period ending 30 June 2023. Q2 and First Half 2023 Highlights  Corporate · Completed strategic review, initiating the transition to a

Lucara Announces Extension of Working Capital Facility

VANCOUVER, BC, Aug. 23, 2023 /CNW/ - (LUC – TSX, LUC – BSE, LUC – Nasdaq Stockholm)   Lucara Diamond Corp. (“Lucara” or the “Company”) announces the short-term extension of the maturity of its $50 million senior secured working capital facility (the “WCF”) and a deferral to November 1, 2023 of the requirement to place $52.9 million in a cost overrun reserve account (the “CORA") by September 2, 2023.  The CORA balance is currently $18.3 million. All currency figures are in U.S. Dollars, unless otherwise stated.   The Company’s debt package consists of two facilities (the “

Nordea Bank Abp: Repurchase of own shares on 23.08.2023

Nordea Bank AbpStock exchange release – Changes in company’s own shares23.08.2023 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 23.08.2023 completed repurchases of own shares (ISIN: FI4000297767) as follows: +----------+-------+-------------------+-------------------+| Trading |Number | Weighted average |Total cost, EUR* **||venue (MIC| of |price / share, EUR*| || Code) |shares | ** | |+----------+-------+-------------------+-------------------+|XHEL |176,673|10.00 |1,766,977.

Everfuel presents second quarter 2023 results on 30 August

Herning, 23 August 2023 – Everfuel A/S will release its financial results for the second quarter of 2023 on Wednesday, 30 August at 08:00 CEST. CEO Jacob Krogsgaard will present the company's results at 09:00 CEST and invite investors, analysts, and media to join the live webcast presentation. The presentation is expected to last up to one hour, including Q&A, and can be followed via live webcast.  Webcast: Join the results webcast on Teams via the following link: Everfuel second quarter 2023 live presentation 

Invitation to Immunovia’s Q2 presentation

LUND (SWEDEN) – Immunovia will publish its second quarter 2023 results on August 30, 2023 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report together with the presentation slides will be available at www.immunovia.com Jeff Borcherding, CEO and President, and Karin Almqvist Liwendahl, CFO, will present on Immunovia’s development. The presentation will be held in English and be followed by a Q&A session. You are welcome to join via webcast or phone, see details below. Telephone numbers and webcastCall any of

Cereno Scientific launches initiative for data quality control of CardioMEMS HF System providing an opportunity to report early efficacy data in Q4

Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced an initiative to control the data quality produced from the cutting-edge technology CardioMEMS HF System (Abbott Inc.) used to daily monitor blood pressure in the pulmonary circulation and other cardio-pulmonary hemodynamics during the Phase II study of CS1. The remarkable patient case study presented in June triggered the initiative for data quality control of CardioMEMS measurements to ensure optimal data quality for CS1 in this study.

Transaction in Own Shares

FIDELITY CHINA SPECIAL SITUATIONS PLC TRANSACTION IN OWN SHARES The Board of Fidelity China Special Situations Plc ("the Company") announces that on 23 August 2023 the Company bought 70,361 of its own shares for cancellation at a price of 204.391 pence per share.  The Company's issued ordinary share capital is 566,291,033 shares of which 85,629,548 shares are held in Treasury, which attract no voting rights. Therefore, the total number of voting rights in the Company is 480,661,485. The above figure (480,661,485) may be used by shareholders as the denominator for the

Cereno Scientific to open two new clinics to complete patient recruitment in the Phase II study of CS1 in PAH as top-line results are estimated in Q1 2024

Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that further mitigation strategies have been activated for the Phase II study of CS1 in pulmonary arterial hypertension (PAH) due to slower patient recruitment than anticipated. Two new specialist clinics with large capacities are currently in the start-up phase to open to complete the recruitment of patients fulfilling the study criteria. Consequently, the timeline of the study estimates top-line results to be reported in Q1 2024.The Phase

Second quarter and first half year results 2023

Fornebu, 23[rd] August 2023, Ocean Yield AS (“Ocean Yield” or the “Company”) announces results for the second quarter and first half year of 2023.Highlights  · EBITDA for Q2 2023 was USD 59.1 million and EBITDA adjusted for finance lease effects was USD 86.5 million.  · Net profit for Q2 2023 was USD 27.7 million.  · Strong balance sheet, with an equity ratio of 31.1% and USD 115.9 million in cash.  · Signed an agreement to acquire four LR1 newbuilding product tankers with sustainability-linked long-term bareboat charters to Braskem S.A.. · Agreement with CMB N.V. that

There are no items matching the current filter
There are no more items matching the current filter
Back to top